Skip to content

Contact Lenses With New UV-blocker Manufactured With Different Techniques

Contact Lenses With New UV-blocker Manufactured With Different Techniques

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03475875
Enrollment
92
Registered
2018-03-23
Start date
2018-02-19
Completion date
2018-04-18
Last updated
2019-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attenuation of Bright Light, Correction of Refraction Error

Brief summary

This study is a randomized, 4-visit, double-masked, 2x3 bilateral crossover, dispensing trial. The study lenses will be worn as daily wear (DW) for a period of two weeks each with one of the study lenses being worn twice. Each study lens is expected to be worn at least five (5) days per week for at least six (6) hours per day worn. There will be no washout period between study lenses.

Interventions

senofilcon A with new UV blocker investigational process

senofilcon A with new UV blocker standard process

Sponsors

Johnson & Johnson Vision Care, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Potential subjects must satisfy all of the following criteria to be enrolled in the study: 1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. 2. Appear able and willing to adhere to the instructions set forth in this clinical protocol. 3. Healthy adult males or females age ≥18 years of age with signed informed consent. 4. Eligible presbyopes will be those that wear full distance contact lenses in both eyes, then wear reading glasses over them. 5. The subject is a current spherical soft contact lens wearer (defined as a minimum of 6 hours of DW per day, at least 5 days per week, for a minimum of 1 month prior to the study) and willing to wear the study lenses on a similar basis. 6. Subjects must be able and willing to wear the study lenses at least 6 hours a day, a minimum of 5 days per week. 7. The subject's vertex-corrected spherical equivalent distance refraction must be in the range of -1.00 to -6.00 (inclusive) in each eye. 8. The subject's refractive cylinder must be ≤ -1.00 D in each eye. 9. Have spherocylindrical best corrected visual acuity of 20/25+3 or better in each eye.

Exclusion criteria

* Potential subjects who meet any of the following criteria will be excluded from participating in the study: 1. Currently pregnant or lactating. 2. Any active or ongoing systemic disease (e.g., Sjögren's Syndrome), allergies, infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid arthritis), or other bodily diseases or infections, by self-report, which are known to interfere with contact lens wear and/or participation in the study. 3. Use of systemic medications (e.g., chronic steroid use) that are known to interfere with contact lens wear. Habitual medications taken by successful contact lens wearers are generally considered acceptable. 4. Habitual toric, extended wear, or multifocal contact lens wear. 5. Any current use of ocular medication. 6. Any known hypersensitivity or allergic reaction to Optifree PureMoist. 7. Any previous, or planned (during the course of the study) ocular surgery (e.g., radial keratotomy, PRK, LASIK, etc.). 8. Participation in any contact lens or lens care product clinical trial within 14 days prior to study enrollment. 9. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician). 10. Any active or ongoing ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or corneal distortion. 11. Any Grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA slit-lamp scale. 12. Binocular vision abnormality or strabismus. 13. Any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that would contraindicate contact lens wear.

Design outcomes

Primary

MeasureTime frameDescription
Overall Comfort Score2- Week Follow-up EvaluationOverall comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. Observations from each study period are treated as independent (for the descriptive summary only). The average of all observations for each lens was reported.
Overall Vision Score2- Week Follow-up EvaluationOverall vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. Observations from each study period are treated as independent (for the descriptive summary only). The average of all observations for each lens was reported.

Countries

United States

Participant flow

Recruitment details

A total of 92 subjects were enrolled into this study. Of those enrolled, 91 were dispensed a study lens and 1 subject failed to meet the eligibility criteria. Of the dispensed subjects 83 completed the study while 8 subjects were discontinued.

Participants by arm

ArmCount
Dispensed Subjects
All subjects dispensed at least one study lens.
91
Total91

Withdrawals & dropouts

PeriodReasonFG000FG001
Period 1Adverse Event21
Period 1Lost to Follow-up10
Period 2Adverse Event30
Period 2Protocol Violation01

Baseline characteristics

CharacteristicDispensed Subjects
Age, Continuous31.8 Years
STANDARD_DEVIATION 6.32
Race/Ethnicity, Customized
American Indian or Native Alaska
0 Participants
Race/Ethnicity, Customized
Asian
11 Participants
Race/Ethnicity, Customized
Black or African American
3 Participants
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander
1 Participants
Race/Ethnicity, Customized
Other
7 Participants
Race/Ethnicity, Customized
White
69 Participants
Region of Enrollment
United States
91 Participants
Sex: Female, Male
Female
61 Participants
Sex: Female, Male
Male
30 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 910 / 91
other
Total, other adverse events
0 / 910 / 91
serious
Total, serious adverse events
0 / 910 / 91

Outcome results

Primary

Overall Comfort Score

Overall comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. Observations from each study period are treated as independent (for the descriptive summary only). The average of all observations for each lens was reported.

Time frame: 2- Week Follow-up Evaluation

Population: Subjects that completed all study visits without a major protocol deviation.

ArmMeasureValue (MEAN)Dispersion
TestOverall Comfort Score61.49 Units on a scaleStandard Deviation 21.087
ControlOverall Comfort Score67.27 Units on a scaleStandard Deviation 22.865
Comparison: It was calculated that 80 participants randomized in a 1:1 fashion between the two sequences would have at least 90% power to detect a 5 points difference in mean overall comfort at the 2-week follow-up. Sample size was determined using Stroup's Method (alpha=0.05).95% CI: [-7.7, -0.9]Linear Mixed Model
Primary

Overall Vision Score

Overall vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. Observations from each study period are treated as independent (for the descriptive summary only). The average of all observations for each lens was reported.

Time frame: 2- Week Follow-up Evaluation

Population: Subjects that completed all study visits without a major protocol deviation.

ArmMeasureValue (MEAN)Dispersion
TestOverall Vision Score61.79 Units on a scaleStandard Deviation 17.758
ControlOverall Vision Score64.92 Units on a scaleStandard Deviation 17.444
Comparison: It was calculated that 80 participants randomized in a 1:1 fashion between the two sequences would have at least 90% power to detect a 5 points difference in mean overall comfort at the 2-week follow-up. Sample size was determined using Stroup's Method (alpha=0.05).95% CI: [-4.7, 1]Linear Mixed Model

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026